Megestrolacetaat Teva (Megestrol Acetate)

Megstrol acetate is a synthetic progestogen that binds to intracellular progesterone receptors. This binding alters gene expression, leading to antineoplastic effects in hormone‑responsive tumors and stimulating appetite by affecting hypothalamic centers and glucocorticoid pathways, which together help increase caloric intake and weight.

The appropriate dose of Megestrolacetaat Teva is determined by the prescribing clinician based on the specific indication, patient weight, disease severity, and response to therapy. Dosage regimens can vary widely, so patients should follow the exact instructions provided by their healthcare professional.

Safety data for megstrol acetate in pregnancy and lactation are limited. The drug is generally avoided during pregnancy unless the potential benefit justifies the risk to the fetus. Breastfeeding is not recommended because the medication may be excreted in breast milk and could affect the infant.

To request Megestrolacetaat Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Megstrol acetate is a potent synthetic progestogen with both antineoplastic and appetite‑stimulating properties, distinguishing it from other agents such as medroxyprogesterone acetate, which is primarily used for contraceptive or menstrual indications. The dual activity of megstrol makes it especially useful in cancer‑related cachexia and hormone‑sensitive tumors.

Megestrolacetaat Teva should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from excess moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and potency throughout its shelf life.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Patients should swallow the tablet whole and avoid crushing or chewing unless specifically instructed, to ensure proper absorption and effectiveness.

Serious adverse events include thromboembolic complications (such as deep‑vein thrombosis or pulmonary embolism), severe hyperglycemia or new‑onset diabetes, hepatic dysfunction, and rare cases of Cushingoid syndrome. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if they occur.

Megstrol acetate is contraindicated in individuals with known hypersensitivity to the drug, active thromboembolic disease, uncontrolled diabetes, or severe hepatic impairment. It should also be avoided in pregnant women unless absolutely necessary, and in patients for whom hormonal therapy is contraindicated.